Extracellular Vesicle Targeting Vehicle for BBB-Crossing Dopamine Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Parkinson's disease, such as high doses of dopamine drugs, are ineffective over time due to the blood-brain barrier and can interfere with other brain regions, necessitating a targeted therapeutic strategy.
Innovation Solution
A targeting vehicle comprising an extracellular vesicle with a dopamine transporter antibody conjugated to its transmembrane protein, capable of crossing the blood-brain barrier and specifically binding to dopamine neurons, loaded with drugs like curcumin to regulate Parkinson's disease markers and promote neuronal health.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of dopamine drugs are administered to treat Parkinson's disease, then therapeutic efficacy is improved initially, but therapeutic efficacy diminishes over time due to blood-brain barrier restrictions and non-specific delivery interferes with other brain regions
Solution Approach 1:
The patent uses a targeting vehicle as an intermediary carrier to transport dopamine drugs across the blood-brain barrier. This vehicle includes surface-modified liposomes or exosomes that specifically bind to dopamine transporters on target neurons, enabling selective drug delivery while preventing non-specific distribution to other brain regions. The intermediary structure solves the contradiction by maintaining therapeutic efficacy through targeted delivery while eliminating harmful non-specific effects.
Solution Approach 2:
The patent applies local quality by creating drugs with spatially differentiated properties: the dopamine drug is conjugated to a targeting moiety that confers specific binding capability to dopamine transporters. This creates a heterogeneity in drug distribution, concentrating the therapeutic agent precisely at the target site (dopamine neurons) while minimizing presence in non-target regions, thereby resolving the contradiction between maintaining efficacy and avoiding non-specific interference.
2Reliability
If high doses of dopamine drugs are administered to overcome blood-brain barrier restrictions, then initial therapeutic effect is achieved, but the drugs cannot effectively penetrate the blood-brain barrier over time
Solution Approach 1:
The patent employs parameter changes by modifying the physical and chemical properties of the drug delivery system. The targeting vehicle uses surface-modified liposomes or exosomes with specific surface charges, sizes, and ligand compositions that enable active transport across the blood-brain barrier. These parameter modifications allow the drug to penetrate the barrier effectively without requiring high doses, maintaining therapeutic efficacy while overcoming the penetration limitation.
3Area of stationary object
If dopamine drugs are delivered non-specifically to the CNS, then broad coverage is achieved, but physiological mechanisms in other brain regions are interfered with
Solution Approach 1:
The targeting vehicle serves as a selective intermediary that mediates drug delivery exclusively to dopamine neurons expressing dopamine transporters. This specific binding mechanism ensures that the drug's coverage is concentrated on the intended target population while excluding other brain regions, thereby eliminating interference with non-target physiological mechanisms while maintaining adequate therapeutic coverage.
Solution Approach 2:
The patent creates local quality through targeted drug conjugation, where the dopamine drug is attached to targeting moieties that direct it specifically to dopamine transporters. This results in spatially localized drug action at the intended target sites while leaving other brain regions unaffected, resolving the contradiction between achieving sufficient coverage and avoiding harmful interference with other physiological systems.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The targeting vehicle effectively reduces alpha-synuclein accumulation, suppresses inflammation, upregulates neuroprotective proteins, and promotes dopamine neuron regeneration, thereby delaying disease progression and improving motor function.
Implementation Method 1
The targeting vehicle of the present invention can be loaded with a drug to cross the blood-brain barrier
Implementation Method 2
achieve specific binding to dopamine neurons
Data Source
Figure 1
Figure 2A~2B
Figure 3A
AI summary
A targeting vehicles comprises an extracellular vesicle with a dopamine transporter antibody on a transmembrane protein of the extracellular vesicle, the extracellular vesicle is secreted by a cell transfected with a vector gene, and at least a portion of the vector gene comprises SEQ ID No: 1. The targeting vehicles provided in the present invention can be loaded with drugs and cross the blood-brain barrier to achieve specific binding to dopamine neuron, and regulate the secretion of Parkinson's disease marker proteins and delay the course of Parkinson's disease.